Online inquiry

IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ141MR)

This product GTTS-WQ141MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CA9 gene. The antibody can be applied in Kidney tumours research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001216.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ141MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ320MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ5172MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ13217MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ7313MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ13285MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ1567MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ13585MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ9639MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW